About Lotus
Lotus is a publicly listed company based in Taipei (Taiwan) founded in 1966, and was acquired by Innobic Asia in November 2021. Contract manufacturing for oral solid formulations is offered. It operates on a Direct-to-Consumer (D2C) and Reseller / Distribution model. The company has 31 employees. Lotus has completed 1 acquisition, including Alvogen. Its chief executive, as recorded, is Robert Wessman. Its website lotuspharm.com draws about 15 thousand monthly visits. Its Indian entity Alvogen Pharma (India) Private Limited reported revenue of ₹51.32 Cr. Lotus offers products and services including Oncology Products and Generic Pharmaceuticals. Its focus areas include Pharmaceuticals and Oncology and Generics.
Company details
Lotus is established as an international pharmaceutical entity with a focus on commercializing novel and generic drugs. Headquartered in Taiwan, the company is supported by a robust RD and manufacturing platform across Asia. A diverse portfolio of high-quality, affordable medicines is delivered to markets worldwide. Operations span oncology, generics, and contract research, with over 250 products in the market and more than 100 projects in development. Strategic partnerships and in-house capabilities are leveraged to maintain competitive speed and flexibility in the industry.
- Headquarters Taipei, Taiwan
- Employees 31
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website lotuspharm.com
- Social LinkedIn
- Acquired by Innobic Asia (Nov 2021)
- Legal Name Lotus Pharmaceutical Co., Ltd.
- Indian entity revenue₹51.32 Cr
FY 2025 · -6% YoY
- Indian entity net profit₹7.79 Cr
FY 2025 · 15% margin
- Indian entity EBITDA₹11.25 Cr
FY 2025 · 22% margin
- InvestorsAlvogen
& 2 more
- Employee Count31
- Investments & Acquisitions
- Acquired by
Associated legal entities of Lotus
Lotus operates through Alvogen Pharma (India) Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Alvogen Pharma (India) Private Limited CIN U74900KA2010PTC053204 | Active | 13 Apr 2010 | Bangalore, Karnataka | ₹51.3 Cr | 31 | 4 | View details |
Products & Services of Lotus
Lotus offers a comprehensive portfolio of products and services, including Oncology Products and Generic Pharmaceuticals.
High-quality oncology drugs are developed for global markets.
Affordable generic medicines are produced for various conditions.
Funding Insights of Lotus
- Total Rounds 2
All 2 funding rounds of Lotus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | Post-IPO | – | – | – | |
| Apr 2021 | Post-IPO | – | – | – |
3 investors in total: 3 institutional.
Investors in Lotus
Lotus has secured backing from 3 investors. Prominent investors backing the company include Alvogen, Aztiq and Innobic Asia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Aztiq is engaged in investments within the pharmaceutical and biotech sectors. | 2009 | aztiq.is | Reykjavík, Iceland | |
Pharmaceutical products are developed and marketed globally. | 2009 | alvogen.com | Montville, United States | |
Operates as a CDMO specializing in solid-based drug production. | 2021 | innobicasia.com | Chatuchak, Thailand |
Investor details for Lotus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Alvogen Pharma (India) Private Limited (Lotus)
Alvogen Pharma (India) Private Limited is the primary company behind Lotus. The board of Alvogen Pharma (India) Private Limited currently have 4 directors; the longest-serving is Fjalar Kristjansson, appointed in 2010. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Fjalar Kristjansson DIN 02504768 | Director | 13 Apr 2010 | 16 yrs 7 mo | Alvogen Pharma (India) Private Limited |
| Divya Chandu Patel DIN 03132296 | Nominee Director | 01 May 2010 | 16 yrs 6 mo | Alvogen Pharma (India) Private Limited |
| Saral Thangam DIN 01507119 | Director | 20 Sep 2014 | 12 yrs 2 mo | Alvogen Pharma (India) Private Limited |
| Aditya Nagaraj Bellur DIN 07231827 | Director | 13 Dec 2017 | 8 yrs 11 mo | Alvogen Pharma (India) Private Limited |
People of Lotus
51 people are tracked at Lotus (24 in leadership, 7 in board & advisors, 20 in team); the tracked headcount is 31.
| Name | Role | Group |
|---|---|---|
Robert Wessman | CEO | Leadership |
Bala Krishna | Head Portfolio Management | Leadership |
Bharath Jayaraman | Head of SEA Markets | Leadership |
Petar Vazharov | CEO | Leadership |
Eeling Chan | CFO, Taiwan | Leadership |
Bjartur Shen | Strategies and Finance VP | Leadership |
Prashant Godse | Head of Business Development | Leadership |
Snaevar Vidisson | Director of Export Markets, B2B | Leadership |
Edin Buljubasic | VP, Legal & Compliance | Leadership |
Ella Tsai | Corporate Procurement Head | Leadership |
Ying-Ming Yue | VP, Operations & Supply Chain Management | Leadership |
Gautam Bakshi M.pharm | Head (senior Director) - Global IP Management | Leadership |
Cy Lim | Senior Director, Marketing Excellence APAC | Leadership |
Fiona Lei | Head Of Human Resources | Leadership |
Catherine Lee | Distribution Regulatory Affairs Director, APAC | Leadership |
Kaushik Gupta | Associate Director | Leadership |
Vamsi Kiran Kosaraju | VP, Quality | Leadership |
Lucian Marcu | Director Supply Chain Management | Leadership |
Shubhashlok Dwibedy | A.i. Head (sales And Marketing) - Philippines | Leadership |
Evelyn Leo | Senior Director | Leadership |
31 more people are available in the full profile.
Complete people profiles for Lotus
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Lotus
Lotus is a publicly listed company on the TWSE with ticker symbol 1795 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Dec 2007
- Listed onTPE: 1795
- Listed entityLotus Pharmaceutical Co., Ltd.
- Exchange sectorHealth technology
- ISINTW0001795003
- Share price180.00 TWD (+1.12% on the day) · 2026-10-14
- Market capitalisation47,364,155,151.00 TWD
- Price to earnings12.7
- EPS (diluted, trailing year)14.22 TWD
- Dividend yield1.4%
- Volume (last session)514,745
Financials of Lotus
Figures of Alvogen Pharma (India) Private Limited, the primary company behind Lotus, for FY 2025. Revenue was ₹51.32 Cr (-6% year on year). Net profit was ₹7.79 Cr (15% margin). EBITDA was ₹11.25 Cr (22% margin). Revenue has grown at a compounded annual rate of +54% over three years and -2% over five years.
- ₹51.32 CrRevenue · FY 2025 · -6% YoY
- ₹7.79 CrNet profit · 15% margin
- ₹11.25 CrEBITDA · 22% margin
- ₹51.2 LakhPaid-up capital
- 31Employees (provident fund records)
- +54%Revenue CAGR, 3 years
- -2%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 20.51B TWD | 4.72B TWD | 7.44B TWD |
| 2024 | 18.58B TWD | 5.07B TWD | 7.30B TWD |
| 2023 | 16.96B TWD | 4.11B TWD | 6.11B TWD |
| 2022 | 14.63B TWD | 3.02B TWD | 5.05B TWD |
| 2021 | 12.65B TWD | 1.40B TWD | 3.05B TWD |
Balance sheet, profit and loss, cash flow and ratios of Alvogen Pharma (India) Private Limited are on its company page.
Detailed financial statements for Lotus
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lotus
Lotus has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Alvogen.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Pharmaceutical products are developed and marketed globally. | alvogen.com | Montville, United States | 2009 | Sep 2025 | $658M |
Complete acquisition details for Lotus
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Lotus
7 dated milestones of Lotus across 59 years, from founding to its latest funding, stage changes and deals.
- Founded Lotus is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Alvogen.
- Funding First funding round.
- Funding Latest funding round, Post-IPO,.
- Exit Acquired by Innobic Asia.
- Acquisition Acquires Alvogen.
Web traffic of Lotus
The website of Lotus (lotuspharm.com) receives about 14.7K visits a month.
- Monthly visits14.7K
▼ 2.3% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lotus
Complete news archive for Lotus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lotus
Lotus was founded in 1966 and raised its 1st funding round 55 years after it was founded.
Lotus is headquartered in Taipei, Taiwan.
Robert Wessman is the CEO of Lotus, as recorded in our data.
Lotus has 31 employees.
The primary company behind Lotus, Alvogen Pharma (India) Private Limited, reported revenue of ₹51.32 Cr for FY 2025, down 6% year on year.
Lotus is established as an international pharmaceutical entity with a focus on commercializing novel and generic drugs. Headquartered in Taiwan, the company is supported by a robust RD and manufacturing platform across Asia. A diverse portfolio of high-quality, affordable medicines is delivered to markets worldwide. Operations span oncology, generics, and contract research, with over 250 products in the market and more than 100 projects in development. Strategic partnerships and in-house capabilities are leveraged to maintain competitive speed and flexibility in the industry.
Lotus offers Oncology Products and Generic Pharmaceuticals.
Yes, Lotus is publicly traded on TWSE under the ticker symbol 1795.
Lotus has made 1 acquisition, including Alvogen.
Lotus has 3 investors. Key investors include Alvogen, Aztiq, and Innobic Asia.
Lotus operates through Alvogen Pharma (India) Private Limited.
Yes. Lotus was acquired by Innobic Asia in November 2021.

